12:00 AM
 | 
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Eribulin mesylate regulatory update

FDA extended the PDUFA date for an NDA from Eisai for eribulin mesylate by 3 months to Dec. 30 from Sept. 30. The NDA is under...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >